Core Viewpoint - TScan Therapeutics, Inc. (TCRX) is experiencing significant selling pressure but is positioned for a potential trend reversal due to being in oversold territory and positive earnings outlook from analysts [1]. Group 1: Stock Performance - TCRX has declined by 5.6% over the past four weeks, indicating a downward trend [1]. - The current Relative Strength Index (RSI) for TCRX is 25.67, suggesting that heavy selling may be exhausting itself [5]. Group 2: Analyst Sentiment - There is strong consensus among Wall Street analysts that TCRX will report better earnings than previously predicted, with a 0.9% increase in the consensus EPS estimate over the last 30 days [6]. - TCRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [7]. Group 3: Technical Indicators - The RSI is a momentum oscillator that helps identify oversold conditions, typically when the reading falls below 30 [2]. - The RSI assists investors in spotting potential entry opportunities when a stock is undervalued due to unwarranted selling pressure [3].

Core Viewpoint - TScan Therapeutics, Inc. has secured a significant investment of approximately $30 million from Lynx1 Capital Management LP, which reflects a 37% premium over the last closing price of its common stock, indicating strong investor confidence in the company's mission to develop TCR-T cell therapies for cancer treatment [1][5]. Company Overview - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [5][10]. - The company is developing its lead TCR-T therapy candidates for hematologic malignancies and has ongoing clinical trials, including the ALLOHATM Phase 1 heme trial and the PLEXI-TTM Phase 1 solid tumor trial [10]. Financial Details - The investment involves the sale of pre-funded warrants to purchase up to 7,500,000 shares of voting common stock at a price of $4.00 per warrant, with an exercise price of $0.0001 per share [5]. - Following this financing, the company expects its cash resources to fund operations into the first quarter of 2027, extending its financial runway beyond previous estimates [9].

WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) --  TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced it has been named one of the Top Places to Work in Massachusetts in the 17th annual, employee-based survey from The Boston Globe. The 2024 Top Places to Work issue was published online at Globe.com/TopPlaces and will appear in Globe M ...

Core Viewpoint - TScan Therapeutics, Inc. reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.28, indicating a positive earnings surprise of 10.71% [1] Financial Performance - The company posted revenues of $1.05 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 63.36%, and a decline from $3.89 million in the same quarter last year [2] - Over the last four quarters, TScan Therapeutics has surpassed consensus EPS estimates three times [2] Stock Performance - TScan Therapeutics shares have decreased by approximately 2.2% since the beginning of the year, contrasting with the S&P 500's gain of 25.8% [3] Future Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.28 on revenues of $6.19 million, and for the current fiscal year, it is -$1.17 on revenues of $10.15 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which TScan Therapeutics belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------- ...

Exhibit 99.1 TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Upcoming oral presentation for the ALLOHA TM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10th at 8:00 a.m. ET to discuss clinical updates from the ALLOHA Phase 1 trial and heme development strategy On track to dose first patient with multiplex TCR-T therapy and ...

TScan Therapeutics, Inc. (TCRX) shares soared 7.6% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.4% loss over the past four weeks.The company is developing its lead TCR-T therapy candidates, TSC-100 and TSC-101, in an early-stage study for treating patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. TScan is also deve ...

All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT with reduced intensity conditioning Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, at 8:00 a.m. ET WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology c ...

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually. Poster Presentation Details: Title: Disco ...

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 6.67%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.32, delivering a surprise of -28%. Over the last four quarters, the company has ...